Literature DB >> 15955688

Cochrane systematic reviews of treatments for lung cancer.

K M Fong1, I A Yang, P V Zimmerman, R V Bowman.   

Abstract

Morbidity and mortality from lung cancer is a major burden to global health. The integration of expert clinical experience, patient preference and high-quality evidence, including Cochrane systematic reviews, can only help improve outcomes from this highly lethal condition.

Entities:  

Mesh:

Year:  2005        PMID: 15955688     DOI: 10.1016/j.rmed.2005.05.002

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  3 in total

1.  Personalized choice of maintenance therapies in non-small-cell lung cancer.

Authors:  N Blais; L Corrales-Rodriguez
Journal:  Curr Oncol       Date:  2012-06       Impact factor: 3.677

2.  Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth.

Authors:  Hua Zhong; Baohui Han; Irina L Tourkova; Anna Lokshin; Alan Rosenbloom; Michael R Shurin; Galina V Shurin
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

3.  Maintenance treatment with chemotherapy and immunotherapy in non-small cell lung cancer: a case report.

Authors:  Anabella Llanos; Mariana Savignano; Gabriela Cinat
Journal:  Front Oncol       Date:  2012-10-26       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.